Tocagen (TOCA) Stock Price, News & Analysis

Company Overview

Tocagen Inc., a clinical-stage cancer-selective gene therapy company, focuses on developing and commercializing product candidates designed to activate a patient's immune system against their cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to deliver therapeutic genes into the DNA of cancer cells. The company's lead product candidate is Toca 511 & Toca FC that is under Phase III clinical trial for recurrent high-grade glioma. It is also developing Toca 511 & Toca FC in a Phase Ib clinical trial for intravenous treatment of advanced cancers. In addition, the company is developing other RRVs to deliver genes to cancer cells against validated immunotherapy targets. The company has a license agreement with ApolloBio to develop and commercialize Toca 511 & Toca FC; and a collaboration agreement with NRG Oncology to develop a clinical trial utilizing Toca 511 & Toca FC for the treatment of patients with newly diagnosed glioblastoma. Tocagen Inc. was founded in 2007 and is based in San Diego, California.

Key Stats

• Today's Range: $4.11 to $4.43
• 50-Day Range: $1.26 to $41.03
• 52-Week Range: $0.42 to $6.77
• Volume: 26,002 shs
• Average Volume: 1.47 million shs
• Market Capitalization: $99.98 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

TOCA Stock Analysis - Frequently Asked Questions

How were Tocagen's earnings last quarter?

Tocagen Inc (NASDAQ:TOCA) released its earnings results on Thursday, April, 23rd. The company reported ($0.43) EPS for the quarter, beating the consensus estimate of ($0.44) by $0.01. Tocagen had a negative net margin of 176,433.34% and a negative trailing twelve-month return on equity of 327.74%.

When did Tocagen IPO?

Tocagen (TOCA) raised $80 million in an initial public offering (IPO) on Thursday, April 13th 2017. The company issued 7,300,000 shares at $10.00-$12.00 per share. Leerink Partners, Evercore ISI and Stifel acted as the underwriters for the IPO.

What other stocks do shareholders of Tocagen own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Tocagen investors own include VBI Vaccines (VBIV), Selecta Biosciences (SELB), Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), T2 Biosystems (TTOO), Bristol-Myers Squibb (BMY) and Catalyst Pharmaceuticals (CPRX).

Company Calendar

• Last Earnings: 4/23/2020
• Today: 11/04/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical Preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:TOCA
• CUSIP: N/A
• CIK: 1419041
• Web: www.tocagen.com
• Phone: 858-412-8400
• Fax: N/A
• Employees: 77
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($2.69)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-63,520,000.00
• Net Margins: -176,433.34%
• Pretax Margin: N/A
• Return on Equity: -327.74%
• Return on Assets: -111.87%

Debt

• Debt-to-Equity Ratio: 1.88
• Current Ratio: 1.15
• Quick Ratio: 1.15

Sales & Book Value

• Annual Sales: $40,000.00
• Price / Sales: 2,499.54
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.45 per share
• Price / Book: 9.29

Miscellaneous

• Outstanding Shares: 23,919,000
• Free Float: N/A
• Market Cap: $99.98 million
• Optionable: Not Optionable
• Beta: 0.01